Safety, pharmacokinetics, and pharmacodynamics of TV‐1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|5|573-583

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.5, 2015-05, pp. : 573-583

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 787-797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial

By Sasaki Takashi   Seino Yutaka   Fukatsu Atsushi   Sakai Soichi   Samukawa Yoshishige  

Advances in Therapy, Vol. 31, Iss. 3, 2014-03 ,pp. : 345-361

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1031-1041

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 7, 2015-04 ,pp. : 636-648

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Multiple‐Ascending‐Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK‐875, in Subjects With Type 2 Diabetes

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 1, 2012-07 ,pp. : 29-39

John Wiley & Sons Inc

Access to resources Recommend Favorite